Actively Recruiting
Adaptive Radiation for Abdominopelvic Metastases
Led by Fox Chase Cancer Center · Updated on 2025-10-29
30
Participants Needed
1
Research Sites
304 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Single arm Phase I trial of adaptive stereotactic body radiation (SBRT) for abdominopelvic metastases. Adaptive SBRT will allow for escalation of the prescription dose and target coverage while maintaining grade 3+ toxicity no greater than 10%. Subjects with metastatic cancer to the abdomen or pelvis requiring local control or palliation will be enrolled.
CONDITIONS
Official Title
Adaptive Radiation for Abdominopelvic Metastases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 18 years
- Histologically or cytologically confirmed metastatic solid tumor in the abdomen or pelvis
- At least one measurable target lesion untreated by prior radiation or interventional radiology
- ECOG performance status 0 or 1
- Estimated survival of at least 12 months
- Normal organ and marrow function including neutrophils > 1,500/mcL, platelets > 100,000/mcL, total bilirubin < 2 mg/dL, AST/ALT < 5 times upper limit of normal, and creatinine < 1.5 times upper limit of normal or creatinine clearance ≥ 50 ml/min/1.73 m2
- Ability to understand and sign informed consent and HIPAA documents
You will not qualify if you...
- Ongoing toxicity from prior therapy greater than Grade 1, except sensory neuropathy, alopecia, or fatigue
- Receiving any other investigational agents
- Known peritoneal carcinomatosis on imaging
- Active solid tumors outside the abdomen or pelvis on imaging
- Six or more active metastatic sites
- Prior radiotherapy to any target metastatic lesion
- Uncontrolled illnesses like infection, symptomatic heart failure, unstable angina, arrhythmia, or psychiatric illness limiting study compliance
- Any condition or comorbidity preventing safe delivery of SBRT per physician judgment
- Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
Actively Recruiting
Research Team
T
Tanu Singh
CONTACT
J
Joshua Meyer, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here